2GMX

Selective Aminopyridine-Based C-Jun N-terminal Kinase inhibitors with cellular activity


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.5 Å
  • R-Value Free: 0.351 
  • R-Value Work: 0.266 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Aminopyridine-Based c-Jun N-Terminal Kinase Inhibitors with Cellular Activity and Minimal Cross-Kinase Activity.

Szczepankiewicz, B.G.Kosogof, C.Nelson, L.T.Liu, G.Liu, B.Zhao, H.Serby, M.D.Xin, Z.Liu, M.Gum, R.J.Haasch, D.L.Wang, S.Clampit, J.E.Johnson, E.F.Lubben, T.H.Stashko, M.A.Olejniczak, E.T.Sun, C.Dorwin, S.A.Haskins, K.Abad-Zapatero, C.Fry, E.H.Hutchins, C.W.Sham, H.L.Rondinone, C.M.Trevillyan, J.M.

(2006) J.Med.Chem. 49: 3563-3580

  • DOI: 10.1021/jm060199b
  • Also Cited By: 2H96

  • PubMed Abstract: 
  • The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and i ...

    The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and irradiation. They have been implicated in the pathology of a variety of different diseases with an inflammatory component including asthma, stroke, Alzheimer's disease, and type 2 diabetes mellitus. In this work, high-throughput screening identified a JNK inhibitor with an excellent kinase selectivity profile. Using X-ray crystallography and biochemical screening to guide our lead optimization, we prepared compounds with inhibitory potencies in the low-double-digit nanomolar range, activity in whole cells, and pharmacokinetics suitable for in vivo use. The new compounds were over 1,000-fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38alpha, and p38delta and showed little inhibitory activity against a panel of 74 kinases.


    Related Citations: 
    • Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors.
      Liu, M.,Xin, Z.,Clampit, J.E.,Wang, S.,Gum, R.J.,Haasch, D.L.,Trevillyan, J.M.,Abad-Zapatero, C.,Fry, E.H.,Sham, H.L.,Liu, G.
      (2006) Bioorg.Med.Chem.Lett. 16: 2590


    Organizational Affiliation

    Metabolic Disease Research, Global Pharmaceutical Research and Discovery Organization, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-6098, USA. bruce.szczepankiewicz@abbott.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Mitogen-activated protein kinase 8
A, B
370Homo sapiensMutation(s): 2 
Gene Names: MAPK8 (JNK1, PRKM8, SAPK1, SAPK1C)
EC: 2.7.11.24
Find proteins for P45983 (Homo sapiens)
Go to Gene View: MAPK8
Go to UniProtKB:  P45983
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
C-jun-amino-terminal kinase-interacting protein 1
F, G
11Homo sapiensMutation(s): 0 
Gene Names: MAPK8IP1 (IB1, JIP1, PRKM8IP)
Find proteins for Q9UQF2 (Homo sapiens)
Go to Gene View: MAPK8IP1
Go to UniProtKB:  Q9UQF2
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SO4
Query on SO4

Download SDF File 
Download CCD File 
A, B
SULFATE ION
O4 S
QAOWNCQODCNURD-UHFFFAOYSA-L
 Ligand Interaction
877
Query on 877

Download SDF File 
Download CCD File 
A, B
N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE
C18 H19 Br N4 O4
GKODDLYLEKSDJL-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
877IC50: 77 nM (99) BINDINGDB
877IC50: 77 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 3.5 Å
  • R-Value Free: 0.351 
  • R-Value Work: 0.266 
  • Space Group: P 32 2 1
Unit Cell:
Length (Å)Angle (°)
a = 150.786α = 90.00
b = 150.786β = 90.00
c = 118.660γ = 120.00
Software Package:
Software NamePurpose
ADSCdata collection
CNXphasing
CNXrefinement
HKL-2000data scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2006-04-07 
  • Released Date: 2006-06-06 
  • Deposition Author(s): Abad-Zapatero, C.

Revision History 

  • Version 1.0: 2006-06-06
    Type: Initial release
  • Version 1.1: 2008-05-01
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance